{"entity":{"id":"da-trial-expedition3","kind":"trial","name":"EXPEDITION 3","aka":[],"tldr":"EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result.","summary":"A large phase 3 trial of an amyloid antibody that did not slow clinical decline as designed. Listed so the pipeline layer includes failures, not only approvals.","status":"negative","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT01900665","url":"https://clinicaltrials.gov/study/NCT01900665"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01900665","phase":"3","setting":"Mild Alzheimer’s disease","sponsor":"Eli Lilly","result":"Primary endpoint not met.","yearReported":2016,"enrolled":2129,"outcomes":[{"endpoint":"Primary clinical endpoint","primary":true,"arms":[{"name":"Solanezumab","note":"Did not meet the primary endpoint"},{"name":"Placebo"}],"source":"https://clinicaltrials.gov/study/NCT01900665"}]},"route":"/trials/da-trial-expedition3/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"}],"company":[{"id":"da-lilly","kind":"company","name":"Eli Lilly","route":"/companies/da-lilly/"}],"roadmap":[{"id":"da-roadmap-anti-amyloid","kind":"roadmap","name":"Anti-amyloid medicines","route":"/roadmaps/da-roadmap-anti-amyloid/"}]}}